Standard BioTools Inc. (NASDAQ: LAB) Stock Competitors & Peer Comparison
See LAB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LAB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LAB | $0.69 | +0.95% | 270.9M | -9.89 | -$0.07 | N/A |
| ALC | $69.12 | -1.96% | 33.7B | 21.74 | $3.18 | +0.52% |
| STE | $218.44 | -2.74% | 21.3B | 20.98 | $10.42 | +1.18% |
| QDEL | $13.38 | -4.22% | 912.4M | 9.99 | $1.34 | N/A |
| MLAB | $123.74 | -3.16% | 692.4M | 12.49 | $9.91 | +0.51% |
| BWAY | $14.16 | +0.07% | 555.4M | 35.97 | $0.39 | N/A |
| SI | $19.99 | -1.62% | 415M | -10.45 | -$1.91 | N/A |
| MASS | $9.81 | -2.39% | 402.5M | -16.35 | -$0.60 | N/A |
| MOBI | $11.09 | -4.64% | 368.7M | -0.59 | -$18.78 | N/A |
| ANIK | $21.04 | +1.11% | 281.6M | 42.94 | $0.49 | N/A |
Stock Comparison
Alcon Inc. (NYSE: ALC)
LAB vs ALC Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, ALC has a market cap of 33.7B. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while ALC trades at $69.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas ALC's P/E ratio is 21.74. In terms of profitability, LAB's ROE is -0.18%, compared to ALC's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to ALC. This indicates higher risk in terms of short-term price fluctuations for LAB.Check ALC's competition here
STERIS plc (NYSE: STE)
LAB vs STE Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, STE has a market cap of 21.3B. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while STE trades at $218.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas STE's P/E ratio is 20.98. In terms of profitability, LAB's ROE is -0.18%, compared to STE's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to STE. This indicates higher risk in terms of short-term price fluctuations for LAB.Check STE's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
LAB vs QDEL Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, QDEL has a market cap of 912.4M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while QDEL trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas QDEL's P/E ratio is 9.99. In terms of profitability, LAB's ROE is -0.18%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, LAB is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for LAB.Check QDEL's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
LAB vs MLAB Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, MLAB has a market cap of 692.4M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while MLAB trades at $123.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas MLAB's P/E ratio is 12.49. In terms of profitability, LAB's ROE is -0.18%, compared to MLAB's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for LAB.Check MLAB's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
LAB vs BWAY Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, BWAY has a market cap of 555.4M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while BWAY trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas BWAY's P/E ratio is 35.97. In terms of profitability, LAB's ROE is -0.18%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, LAB is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for LAB.Check BWAY's competition here
Shoulder Innovations, Inc. (NYSE: SI)
LAB vs SI Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, SI has a market cap of 415M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while SI trades at $19.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas SI's P/E ratio is -10.45. In terms of profitability, LAB's ROE is -0.18%, compared to SI's ROE of -0.26%. Regarding short-term risk, LAB is more volatile compared to SI. This indicates higher risk in terms of short-term price fluctuations for LAB.Check SI's competition here
908 Devices Inc. (NASDAQ: MASS)
LAB vs MASS Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, MASS has a market cap of 402.5M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while MASS trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas MASS's P/E ratio is -16.35. In terms of profitability, LAB's ROE is -0.18%, compared to MASS's ROE of -0.25%. Regarding short-term risk, LAB is more volatile compared to MASS. This indicates higher risk in terms of short-term price fluctuations for LAB.Check MASS's competition here
Mobia Medical, Inc. Common Stock (NASDAQ: MOBI)
LAB vs MOBI Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, MOBI has a market cap of 368.7M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while MOBI trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas MOBI's P/E ratio is -0.59. In terms of profitability, LAB's ROE is -0.18%, compared to MOBI's ROE of -15.96%. Regarding short-term risk, LAB is more volatile compared to MOBI. This indicates higher risk in terms of short-term price fluctuations for LAB.Check MOBI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
LAB vs ANIK Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, ANIK has a market cap of 281.6M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while ANIK trades at $21.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas ANIK's P/E ratio is 42.94. In terms of profitability, LAB's ROE is -0.18%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, LAB is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for LAB.Check ANIK's competition here
Trinity Biotech plc (NASDAQ: TRIB)
LAB vs TRIB Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, TRIB has a market cap of 184.7M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while TRIB trades at $9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas TRIB's P/E ratio is -0.15. In terms of profitability, LAB's ROE is -0.18%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, LAB is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for LAB.Check TRIB's competition here
Edap Tms S.a. (NASDAQ: EDAP)
LAB vs EDAP Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas EDAP's P/E ratio is -5.80. In terms of profitability, LAB's ROE is -0.18%, compared to EDAP's ROE of -3.13%. Regarding short-term risk, LAB is more volatile compared to EDAP. This indicates higher risk in terms of short-term price fluctuations for LAB.Check EDAP's competition here
Nyxoah S.A. (NASDAQ: NYXH)
LAB vs NYXH Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, NYXH has a market cap of 162.1M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while NYXH trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas NYXH's P/E ratio is -0.64. In terms of profitability, LAB's ROE is -0.18%, compared to NYXH's ROE of -1.80%. Regarding short-term risk, LAB is more volatile compared to NYXH. This indicates higher risk in terms of short-term price fluctuations for LAB.Check NYXH's competition here
Apyx Medical Corporation (NASDAQ: APYX)
LAB vs APYX Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, APYX has a market cap of 128.4M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while APYX trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas APYX's P/E ratio is -15.25. In terms of profitability, LAB's ROE is -0.18%, compared to APYX's ROE of -0.79%. Regarding short-term risk, LAB is more volatile compared to APYX. This indicates higher risk in terms of short-term price fluctuations for LAB.Check APYX's competition here
SkinHealth Systems Inc. (NASDAQ: SKIN)
LAB vs SKIN Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, SKIN has a market cap of 95.5M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while SKIN trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas SKIN's P/E ratio is -3.35. In terms of profitability, LAB's ROE is -0.18%, compared to SKIN's ROE of -0.48%. Regarding short-term risk, LAB is less volatile compared to SKIN. This indicates lower risk in terms of short-term price fluctuations for LAB.Check SKIN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
LAB vs DRIO Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, DRIO has a market cap of 51.4M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while DRIO trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas DRIO's P/E ratio is -1.20. In terms of profitability, LAB's ROE is -0.18%, compared to DRIO's ROE of +1.04%. Regarding short-term risk, LAB is more volatile compared to DRIO. This indicates higher risk in terms of short-term price fluctuations for LAB.Check DRIO's competition here
Spectral AI, Inc. (NASDAQ: MDAI)
LAB vs MDAI Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, MDAI has a market cap of 51.2M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while MDAI trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas MDAI's P/E ratio is -3.58. In terms of profitability, LAB's ROE is -0.18%, compared to MDAI's ROE of +1.21%. Regarding short-term risk, LAB is more volatile compared to MDAI. This indicates higher risk in terms of short-term price fluctuations for LAB.Check MDAI's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
LAB vs BEAT Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, BEAT has a market cap of 24.7M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while BEAT trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas BEAT's P/E ratio is -0.87. In terms of profitability, LAB's ROE is -0.18%, compared to BEAT's ROE of -6.87%. Regarding short-term risk, LAB is more volatile compared to BEAT. This indicates higher risk in terms of short-term price fluctuations for LAB.Check BEAT's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
LAB vs BEATW Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, BEATW has a market cap of 7.8M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while BEATW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas BEATW's P/E ratio is -0.02. In terms of profitability, LAB's ROE is -0.18%, compared to BEATW's ROE of -6.87%. Regarding short-term risk, LAB is more volatile compared to BEATW. This indicates higher risk in terms of short-term price fluctuations for LAB.Check BEATW's competition here
WORK Medical Technology Group Ltd. Class A (NASDAQ: WOK)
LAB vs WOK Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, WOK has a market cap of 5M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while WOK trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas WOK's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.18%, compared to WOK's ROE of -0.19%. Regarding short-term risk, LAB is more volatile compared to WOK. This indicates higher risk in terms of short-term price fluctuations for LAB.Check WOK's competition here
QTREX Quantum Ltd. Warrant (NASDAQ: QTEXW)
LAB vs QTEXW Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while QTEXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas QTEXW's P/E ratio is -0.01. In terms of profitability, LAB's ROE is -0.18%, compared to QTEXW's ROE of N/A. Regarding short-term risk, LAB is less volatile compared to QTEXW. This indicates lower risk in terms of short-term price fluctuations for LAB.Check QTEXW's competition here
ENvue Medical, Inc. (NASDAQ: FEED)
LAB vs FEED Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, FEED has a market cap of 3.3M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while FEED trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas FEED's P/E ratio is -0.03. In terms of profitability, LAB's ROE is -0.18%, compared to FEED's ROE of -0.60%. Regarding short-term risk, LAB is less volatile compared to FEED. This indicates lower risk in terms of short-term price fluctuations for LAB.Check FEED's competition here
iTonic Holdings Ltd. (NASDAQ: ITOC)
LAB vs ITOC Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, ITOC has a market cap of 2.9M. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while ITOC trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas ITOC's P/E ratio is -0.99. In terms of profitability, LAB's ROE is -0.18%, compared to ITOC's ROE of -0.94%. Regarding short-term risk, LAB is less volatile compared to ITOC. This indicates lower risk in terms of short-term price fluctuations for LAB.Check ITOC's competition here
Tivic Health Systems, Inc. (NASDAQ: TIVC)
LAB vs TIVC Comparison September 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 270.9M. In comparison, TIVC has a market cap of 279.2K. Regarding current trading prices, LAB is priced at $0.69 on the NASDAQ, while TIVC trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -9.89, whereas TIVC's P/E ratio is -0.04. In terms of profitability, LAB's ROE is -0.18%, compared to TIVC's ROE of -1.65%. Regarding short-term risk, LAB is less volatile compared to TIVC. This indicates lower risk in terms of short-term price fluctuations for LAB.Check TIVC's competition here